3.29

3.13% 0.10

After Hours: 3.20 -0.09 -2.74%

Macrogenics Inc (MGNX)

Overview News Price History Option Chain Financials Discussions Forecast

Macrogenics Inc stock is traded at $3.29, with a volume of 525.59K. It is up +3.13% in the last 24 hours and down -6.27% over the past month. Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 × CTLA-4), Tebotelimab (PD-1 × LAG-3), MGD024 (CD123 × CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV × CD3).

Previous Close:

$3.19

Open:

$3.2

24h Volume:

525.59K

Relative Volume:

0.60

Market Cap:

$203.56M

Revenue:

$56.91M

Net Income/Loss:

$-9.06M

P/E Ratio:

27.42

EPS:

0.12

Net Cash Flow:

$-79.97M

1W Performance:

+7.52%

1M Performance:

-6.27%

6M Performance:

-77.65%

1Y Performance:

-29.40%

1-Day Range:

$3.1576

$3.365

1-Week Range:

$2.9511

$3.365

52-Week Range:

$2.9511

$21.88

Macrogenics Inc Stock (MGNX) Company Profile

Name

Macrogenics Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

301-251-5172

Address

9704 MEDICAL CENTER DRIVE, Rockville, MD

Employee

339

Twitter

@macrogenics

Next Earnings Date

2024-08-07

Latest SEC Filings

MGNX's Discussions on Twitter

Macrogenics Inc Stock (MGNX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-20-23	Upgrade	Citigroup	Neutral → Buy
Nov-07-23	Upgrade	Guggenheim	Neutral → Buy
Mar-17-23	Downgrade	Guggenheim	Buy → Neutral
Nov-22-22	Downgrade	Cowen	Outperform → Market Perform
Nov-14-22	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jul-18-22	Downgrade	SMBC Nikko	Outperform → Neutral
Jul-11-22	Downgrade	BMO Capital Markets	Outperform → Market Perform
May-04-22	Downgrade	Guggenheim	Buy → Neutral
Feb-28-22	Upgrade	Citigroup	Neutral → Buy
Feb-11-22	Initiated	BMO Capital Markets	Outperform
Feb-04-22	Initiated	SMBC Nikko	Outperform
Nov-17-21	Resumed	Guggenheim	Buy
Oct-19-21	Initiated	JMP Securities	Mkt Outperform
Oct-15-21	Resumed	BTIG Research	Buy
Apr-26-21	Resumed	Credit Suisse	Outperform
Mar-12-21	Upgrade	Barclays	Underweight → Overweight
Dec-22-20	Resumed	H.C. Wainwright	Buy
Aug-03-20	Downgrade	Citigroup	Buy → Neutral
Jun-01-20	Upgrade	Guggenheim	Neutral → Buy
May-26-20	Reiterated	H.C. Wainwright	Buy
Mar-04-20	Initiated	Barclays	Underweight
Dec-19-19	Initiated	Cantor Fitzgerald	Overweight
Dec-18-19	Initiated	Cantor Fitzgerald	Overweight
Nov-21-19	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Nov-20-19	Resumed	Guggenheim	Neutral
May-03-19	Upgrade	Wedbush	Neutral → Outperform
Apr-12-19	Initiated	Guggenheim	Neutral
Feb-07-19	Upgrade	Citigroup	Sell → Buy
Feb-07-19	Downgrade	Wedbush	Outperform → Neutral
Feb-06-19	Upgrade	Raymond James	Underperform → Mkt Perform
Feb-04-19	Downgrade	Citigroup	Neutral → Sell
Dec-10-18	Downgrade	Raymond James	Outperform → Underperform
Sep-10-18	Resumed	BTIG Research	Buy
May-31-18	Initiated	Evercore ISI	Outperform
Mar-05-18	Initiated	H.C. Wainwright	Buy
Mar-31-17	Initiated	Raymond James	Outperform

View All

Macrogenics Inc Stock (MGNX) Latest News

12:43 PM